Aurobindo Pharma Limited is a Pharmaceuticals company listed on the National Stock Exchange (NSE) with a market capitalisation of ₹1.05 lakh crore. The company reports ROE of 10.7%, a net profit margin of 10.8%. Revenue grew +23.9% year-over-year. Promoter holding stands at 54.8%, with FII participation at 29.6%.
Buying pressure is building (RSI/MACD momentum confirmed). Trading near its strongest price of the year (within 5% of 52-week high). A trend-following indicator is on the bullish side (SuperTrend signal: buy). The uptrend is visible even on the weekly chart (longer-term trend confirmed). The breakout is happening on lighter-than-normal trading — needs confirmation (below-average volume on breakout bar). Yesterday's candle shape suggests buyers took control (✅ Bullish Engulfing — bullish reversal pattern). Both short and medium-term trend lines are pointing upward — the trend has momentum (rising EMA20 + EMA50). Price is right at the ceiling of this year's range — a close above would be a significant breakout (at 52W high zone). Foreign institutions have been net buyers for 3 consecutive days — sustained institutional demand (✅ FII buying streak).
Aurobindo Pharma Limited scores 75/100 (High Conviction Research Signal). The strongest signals are Trend (14/100) and Momentum (13/100). The weakest dimension is Institutional Activity (1/100), which warrants monitoring. This reflects JaySense quantitative research scoring only — not investment advice. Consult a SEBI Registered Investment Adviser before making any investment decision.
| Stock | Score | Signal |
|---|---|---|
|
SUNPHARMA
Sun Pharmaceutical Industries Limited
|
84 | High Conviction |
|
APOLLOHOSP
Apollo Hospitals Enterprise Limited
|
73 | High Conviction |
|
DIVISLAB
Divi's Laboratories Limited
|
72 | High Conviction |
|
CIPLA
Cipla Limited
|
69 | Positive Setup |
|
GLENMARK
Glenmark Pharmaceuticals Limited
|
60 | Positive Setup |